Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1384489 (
Scratch
)
395
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Opa interacting protein 5
(
OIP5
) has previously been identified as a tumorigenesis gene. The purpose of this study is to explore the role of
OIP5
in the progression of bladder cancer (BC). The
OIP5
expression and clinical behaviors in bladder cancer were collected from lager database. Our study showed that
OIP5
was highly expressed in bladder cancer tissues and cells. Overexpression of
OIP5
in tumor patients predicted worse overall survival (OS) and higher histological grade. Vitro and vivo experiments demonstrated that knockdown of
OIP5
significantly inhibited cell growth of BC.
Scratch
assay and transwell assay suggested that migration capacity of BC cells was decreased after knockdown of
OIP5
. Cisplatin sensitivity assay indicated that depletion of
OIP5
increased the sensitivity of BC cells to cisplatin. Finally, we identified 38 overlapping differentially expressed genes (DEGs) between RNA-seq and TCGA analyses which were closely linked to
OIP5
. Bioinformatics analysis showed that these DEGs enriched in oocyte meiosis, fanconi anemia pathway, cell cycle, and microRNAs regulation. TOP2A, SPAG5, SKA1, EXO1, TK1 were confirmed to associated with bladder cancer development. Our study suggests that
OIP5
may be a potential biomarker for growth, metastasis and drug-resistance in bladder cancer.
...
PMID:OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells. 3058 53
